We obtained results that show gelsolin could serve as a potential biomarker of clinical severity and therapeutic response in psoriasis, in accordance with comparative proteomic data analysis and identification and validation through measurement of serum gelsolin levels. This evidence concerns the gene GSN and psoriasis.